Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Pushback on drug ads

Roger Collier
CMAJ February 16, 2016 188 (3) 176; DOI: https://doi.org/10.1503/cmaj.109-5223
Roger Collier
CMAJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Like most physicians in the United States, Dr. Ryan Gray has seen his share of prescription drug ads on television. Many are cringe-worthy, he says, citing as an example the one he saw recently for a drug to treat opioid-induced constipation.

“This is an example of a drug company creating a disease because they have a medication they can sell for it,” says Gray, a former flight surgeon for the United States Air Force who runs the online resource Medical School Headquarters.

His frustration with pharmaceutical advertising prompted him to write an article called “Get Big Pharma Off of My TV Screen and Out of My House.” According to Gray, US television viewers are bombarded with messages that lead many to believe they are suffering from health problems they don’t actually have. They then visit their doctors and demand the brand-name drugs they saw in ads. And if a doctor doesn’t comply — well, there is always another doctor.

“The presence of ads is getting in the way of the doctor–patient relationship,” says Gray.

The only other country that permits direct-to-consumer advertising of prescription medication is New Zealand. But could that change? Will the US someday leave New Zealand to stand alone by joining the rest of the word in banning consumer drug ads? That would indeed be the case if the American Medical Association (AMA) had its way.

On Nov. 17, 2015, the AMA called for a ban on direct-to-consumer advertising of prescription drugs and medical devices. According to the association’s statement, the billions of dollars spent on marketing by pharmaceutical companies fuels “escalating drug prices” and “inflates demand for new and more expensive drugs, even when these drugs may not be appropriate.”

In response to a request for an update on this issue, an AMA media representative wrote in an email that a “strategy to advance the new AMA policy in support of a consumer ad ban on prescription drugs and devices is under development at the AMA” and said no new information is available.

Figure1

Will US television screens someday be free of pharmaceutical ads?

Image courtesy of AzmanJaka/iStock

It is somewhat surprising that it took this long for the AMA to take a stand against consumer drug ads, says Barbara Mintzes, senior lecturer in the pharmacy faculty at the University of Sydney. The Canadian Medical Association, after all, approved a policy opposing such ads more than 13 years ago.

Considering the success of drug ads in the US, the pharmaceutical industry has attempted to gain permission to advertise to consumers in Canada, Australia and other countries with bans, says Mintzes. So far, none have succeeded. An attempt to allow direct-to-consumer advertising of drugs in the European Union, for example, was voted down 494–42 by European Parliament in 2002.

Getting drug ads off American broadcasts and out of online and print publications won’t be easy. For one, the pharmaceutical industry has a huge lobbying presence in the US. In fact, it tops the list, according to OpenSecrets.org, with $3.2 billion spent on lobbying since 1998. That’s a billion more than the next-biggest spender, the insurance industry. Another reason, says Mintzes, is that the US has “a very strong legal protection of commercial freedom of expression.”

Still, anything is possible, and the AMA is an influential organization. “It certainly has both money and clout,” says Mintzes. “The question is: will they take this policy statement forward and actually have a strategy for how they would work toward implementation.”

But even if the AMA does increase the pressure to ban consumer drugs ads in the US, it’s not likely to happen, according to Dan Jaffe, group executive vice president of government relations for the Association of National Advertisers. “Under our laws, restrictions on speech must be a last resort, not a first resort,” says Jaffe.

Besides, he suggests, if consumers can’t learn about new drugs from pharmaceutical ads, they will simply turn to the Internet, and that information may be inaccurate. The US Food and Drug Administration (FDA) has strong powers to control the content of drugs ads, he notes, so the information they contain can be trusted.

“Of all the categories of advertising, prescription drugs are one of, if not the most, heavily regulated,” says Jaffe. “The odds of false or deceptive advertising are low.”

As for arguments that consumer drug ads lead to unnecessary use of drugs and drive demand for high-priced medications, Jaffe isn’t buying it. Unlike other consumer goods, such as televisions or vehicles, prescription drugs can only be obtained with the consent of a physician.

“You have a highly trained intermediary,” he says. “To make that argument, you have to believe that doctors are incapable of talking to their patients and saying “no” or telling them there is a less expensive alternative.”

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 188 (3)
CMAJ
Vol. 188, Issue 3
16 Feb 2016
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pushback on drug ads
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pushback on drug ads
Roger Collier
CMAJ Feb 2016, 188 (3) 176; DOI: 10.1503/cmaj.109-5223

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Pushback on drug ads
Roger Collier
CMAJ Feb 2016, 188 (3) 176; DOI: 10.1503/cmaj.109-5223
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • What’s important to know about the new COVID-19 variants?
  • Women experts underrepresented in pandemic coverage
  • Feds update immunization advice with Moderna vaccine approval
Show more News

Similar Articles

Collections

  • Topics
    • Global health
    • Drug regulation

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire